Lexaria Celebrates its 70th Patent Award
Key Highlights
- ➤Lexaria (LEXX) reaches 70 granted patents worldwide, with additional applications pending
- ➤US Patent 12,691,163 covers DehydraTECH processes for six GLP-1 molecules
- ➤US Patent 12,758,566 covers DehydraTECH-processed cannabidiol for diabetes applications
- ➤Canadian Patent 3,199,547 covers DehydraTECH-processed CBD for hypertension applications
- ➤European Patent 4522159 covers DehydraTECH-processed CBD for epilepsy applications
Expert Statements
Richard Christopher, CEO of Lexaria Bioscience
“Our IP is our most valuable asset that, as it grows and strengthens, supports our ongoing and accelerating business development programs.”
Richard Christopher, CEO of Lexaria Bioscience
“Lexaria has built a world-class portfolio of patent-protected IP across most of the world's biggest pharmaceutical markets and will continue to build on this in the future.”
KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing research and development ("R&D") programs. The expansion of our IP is recognized and achieved, in part, through new international patent awards.
"Our IP is our most valuable asset that, as it grows and strengthens, supports our ongoing and accelerating business development programs," said Richard Christopher, CEO of Lexaria. "Lexaria has built a world-class portfolio of patent-protected IP across most of the world's biggest pharmaceutical markets and will continue to build on this in the future."
Get started
Create a free account to read the full story.